Name: Diagnosis, Treatment, and Management of COPD and Asthma (en Inglés)
SKU: 57909736
Price: 95200.00 CLP
Availability: InStock
Author: Nishimura, Koichi
ISBN: 9783036589657

portada Diagnosis, Treatment, and Management of COPD and Asthma (en Inglés)

Diagnosis, Treatment, and Management of COPD and Asthma (en Inglés)

Formato

Libro Físico

Editorial

Mdpi AG

Autor

Nishimura, Koichi

Idioma

Inglés

N° páginas

286

Encuadernación

Tapa Dura

Dimensiones

24.4x17x2.4 cm

Peso

0.82 kg.

ISBN13

9783036589657

Categorías

Farmacología

Diagnosis, Treatment, and Management of COPD and Asthma (en Inglés)

Nishimura, Koichi (Autor) · Mdpi AG · Tapa Dura

Libro Nuevo Importado

Envío: 16 a 21 días háb.

$ 173.090$ 95.200

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 95.200

Llega entre el 07 Oct y el 15 Oct a Santiago, Región Metropolitana. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Diagnosis, Treatment, and Management of COPD and Asthma (en Inglés)"

Chronic obstructive pulmonary disease (COPD) is a disorder characterized by airflow limitation and is one of the major causes of mortality and morbidity across the globe. Although several guidelines have been published over the past three decades, they were generated in response to the fact that COPD is a major cause of mortality and morbidity and remains an important social problem. In the 20th century, forced expiratory volume in one second (FEV1) was the single most important measure in patients with COPD from discriminative, evaluative, and predictive standpoints. We found that dyspnea is a better mortality predictor than FEV1 in 2002 and exercise capacity in 2003. Subsequently, it has become apparent that physical activity is more predictive of mortality. Furthermore, we have recently developed the tendency to use the reduction of the future risk of exacerbation as the endpoint of relatively large-scale clinical trials rather than the improvement of FEV1. Many researchers have continued to seek better outcome markers and have also discussed what should be used as primary or secondary endpoints in clinical trials in subjects with COPD. We have undoubtedly made great progress but still have a lot of work to do for the best interests of patients.